Next generation gene control solutions for enhanced cell therapy development
Laverock’s technology platforms can help address the key challenges associated with cell therapy development - efficacy, safety, and precision. Our gene silencing platform takes gene control to the next level – enabling precise, programmable control over gene expression, linking silencing to specific cell identities and states.
While CAR-T therapies have proved transformative for liquid tumours, challenges remain to successfully address solid tumour indications. Laverock technology can tackle these through our programmable, tunable, and multiplex gene silencing approach – targeting key factors to improve efficacy, while maximising safety. Our modular platform can be readily integrated into existing manufacturing workflows as part of next generation products.
Laverock has demonstrated how our technology can be part of a truly scalable, effective and safe platform for the development of iPSC-derived products. By linking gene control to cell identity we can unlock targets which are not amenable to conventional platforms and ensure silencing only occurs in the terminally differentiated or mature cell types. Our modular approach can armour cells across different key attributes, and is supported by our advanced cell engineering platform and workflows.
